127 related articles for article (PubMed ID: 20816259)
21. Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates.
Salvi M; Vannucchi G; Campi I; Currò N; Simonetta S; Covelli D; Pignataro L; Guastella C; Rossi S; Bonara P; Dazzi D; Ratiglia R; Beck-Peccoz P
Clin Immunol; 2009 May; 131(2):360-5. PubMed ID: 19195932
[TBL] [Abstract][Full Text] [Related]
22. [Novel treatment opportunities in Graves' orbitopathy].
Erdei A; Gazdag A; Bodor M; Berta E; Katkó M; Ujhelyi B; Steiber Z; Győry F; Urbancsek H; Barna S; Galuska L; Nagy VE
Orv Hetil; 2014 Aug; 155(33):1295-300. PubMed ID: 25109914
[TBL] [Abstract][Full Text] [Related]
23. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report.
Foster CS; Chang PY; Ahmed AR
Ophthalmology; 2010 May; 117(5):861-9. PubMed ID: 20045562
[TBL] [Abstract][Full Text] [Related]
24. Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab.
Taverna JA; Lerner A; Bhawan J; Demierre MF
J Drugs Dermatol; 2007 Jul; 6(7):731-2. PubMed ID: 17763598
[TBL] [Abstract][Full Text] [Related]
25. [New immunomodulators in treatment of Graves'ophtalmopathy].
Josseaume C; Lorcy Y
Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S29-32. PubMed ID: 18954856
[TBL] [Abstract][Full Text] [Related]
26. Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab.
Schmidt E; Benoit S; Bröcker EB; Zillikens D; Goebeler M
Arch Dermatol; 2006 Feb; 142(2):147-50. PubMed ID: 16490841
[No Abstract] [Full Text] [Related]
27. B-cell targeted therapy with rituximab for thyroid eye disease: closer to the clinic.
Shen S; Chan A; Sfikakis PP; Hsiu Ling AL; Detorakis ET; Boboridis KG; Mavrikakis I
Surv Ophthalmol; 2013; 58(3):252-65. PubMed ID: 23253433
[TBL] [Abstract][Full Text] [Related]
28. Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity.
Zang S; Ponto KA; Kahaly GJ
J Clin Endocrinol Metab; 2011 Feb; 96(2):320-32. PubMed ID: 21239515
[TBL] [Abstract][Full Text] [Related]
29. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic.
Perosa F; Prete M; Racanelli V; Dammacco F
J Intern Med; 2010 Mar; 267(3):260-77. PubMed ID: 20201920
[TBL] [Abstract][Full Text] [Related]
30. Prospects for B-cell-targeted therapy in autoimmune disease.
Edwards JC; Cambridge G
Rheumatology (Oxford); 2005 Feb; 44(2):151-6. PubMed ID: 15509628
[No Abstract] [Full Text] [Related]
31. An open label study of the effects of rituximab in neuromyelitis optica.
Cree BA; Lamb S; Morgan K; Chen A; Waubant E; Genain C
Neurology; 2005 Apr; 64(7):1270-2. PubMed ID: 15824362
[TBL] [Abstract][Full Text] [Related]
32. Peripheral T and B lymphocytes do not correlate with Graves' orbitopathy.
Ionni I; Rotondo Dottore G; Marinò M
J Endocrinol Invest; 2018 Nov; 41(11):1355-1356. PubMed ID: 30182361
[No Abstract] [Full Text] [Related]
33. Intraorbital injection of rituximab: a new approach for active thyroid-associated orbitopathy, a prospective case series.
Savino G; Balia L; Colucci D; Battendieri R; Gari M; Corsello SM; Pontecorvi A; Dickmann A
Minerva Endocrinol; 2013 Jun; 38(2):173-9. PubMed ID: 23732371
[TBL] [Abstract][Full Text] [Related]
34. Successful treatment of autoimmune thrombocytopenic purpura with rituximab in a dialysis patient with systemic lupus erythematosus.
Lee SY; Hsu PY; Juan KC; Chang H; Huang WH; Lai PC
Int Immunopharmacol; 2010 May; 10(5):632-4. PubMed ID: 20172055
[TBL] [Abstract][Full Text] [Related]
35. Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix.
Vugmeyster Y; Howell K; Bakshl A; Flores C; Canova-Davis E
Cytometry A; 2003 Apr; 52(2):101-9. PubMed ID: 12655653
[TBL] [Abstract][Full Text] [Related]
36. Treatment of thyroid-associated orbitopathy with rituximab--a novel therapy for an old disease: case report and literature review.
Madaschi S; Rossini A; Formenti I; Lampasona V; Marzoli SB; Cammarata G; Politi LS; Martinelli V; Bazzigaluppi E; Scavini M; Bosi E; Lanzi R
Endocr Pract; 2010; 16(4):677-85. PubMed ID: 20350915
[TBL] [Abstract][Full Text] [Related]
37. Persistent B-cell depletion after rituximab for thrombocytopenic purpura.
Bisogno G
Eur J Pediatr; 2007 Jan; 166(1):85-6. PubMed ID: 16896642
[No Abstract] [Full Text] [Related]
38. Do glucocorticoids affect outcome in Graves' disease following radioiodine therapy?
Salvatore D; Fenzi G
Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):194-5. PubMed ID: 16932282
[No Abstract] [Full Text] [Related]
39. Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms.
Silverman GJ
Arthritis Rheum; 2006 Aug; 54(8):2356-67. PubMed ID: 16868991
[No Abstract] [Full Text] [Related]
40. Medical Treatment of Graves' Orbitopathy.
Salvi M; Campi I
Horm Metab Res; 2015 Sep; 47(10):779-88. PubMed ID: 26361263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
